Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET

Company Participants

Paul Little - Chief Financial Officer

David-Alexandre Gros - Chief Executive Officer

Steven Perrin - President and Chief Scientific Officer

Conference Call Participants

Pete Stavropoulos - Cantor Fitzgerald

Thomas Smith - SVB Leerink Securities

Matt Kaplan - Ladenburg Thalmann

Rami Katkhuda - LifeSci Capital

Operator

Greetings, and welcome to the Eledon Pharmaceuticals Fourth Quarter and Full-Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded today, March 30, 2023.

At this time, I would now like to turn the conference call over to Paul Little, Chief Financial Officer of Eledon. Please go ahead, sir.

Paul Little

Good afternoon, everyone, and thank you for joining Eledon's fourth quarter and full-year 2022 operating and financial results conference call. I'm joined on today's call by David-Alexandre Gros, Chief Executive Officer; and Steve Perrin, our President and Chief Scientific Officer; Jeff Bornstein, our Chief Medical Officer is not present today, as he is traveling to the World Congress of Nephrology. Earlier today, Eledon issued a press release announcing financial results for the fourth quarter and full-year ended December 31, 2022. You may access the release under the Investors tab on our Company's website at eledon.com.

I would like to remind everyone that statements made during this conference call relating to Eledon's expected future performance, future business prospects or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts due to the impact of many factors beyond the control of Eledon. Eledon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to the risk factors set forth in Eledon's reports filed with the U.S. Securities and Exchange Commission.

Now it's my pleasure to pass the call to Eledon's CEO, Dr. David-Alexandre Gros. DA?

David-Alexandre Gros

Thank you, Paul, and thank you, all for joining the call today. We made the strategic decision as we entered 2023 to primarily focus our financial and organizational resources on our kidney transplantation program to continue to seek non-dilutive financing for ALS program and to deprioritize our IgA nephropathy and islet cell transplant programs. Our rationale was based on the significant existing preclinical data from both tegoprubart, our anti-CD40 ligand antibody and historical anti-CD40 ligand antibodies demonstrating the class's potential in organ transplantation combined with a large potential size of the transplant market, a clear regulatory path that also provides for potential upside using kidney function or another predictive endpoint and the concentration of organ transplantation in the United States across a relatively limited number of hospitals, thus making it possible for smaller sized biotech to tackle from a sales and marketing perspective.